Infection Risk During Rituximab Therapy in Multiple Sclerosis: Effect of Dosing Interval and Age. (PubMed, Neurol Clin Pract) - Oct 10, 2026 - "Extended rituximab intervals are associated with reduced overall infection risk, but the benefit for hospital-treated infections is limited. Age ≥60 years independently increases the risk of hospital-treated infections. These findings support cautious interval extension and careful risk-benefit assessment in older patients."
Journal • Observational data • CNS Disorders • Infectious Disease • Multiple Sclerosis
|
|
Gorm Pihl-Jensen; Jan Harald Aarseth; Kjell-Morten Myhr; Maria Lie Selle; Ola Nakken; Trygve Holmøy; Øivind Torkildsen
|